Durvalumab trials for Breast cancer

All Durvalumab trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Durvalumab for Breast cancer

• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
  NCT06103864 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 320 locations
• A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
  NCT06508216 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 554 locations
• Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
  NCT05720260 · Phase: Phase 2 · Ages: 20 Years and older · Sex: Female · 1 location
• Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
  NCT06954480 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
  NCT03740893 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
  NCT05582538 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• TRUDI: TDXD+Durva in HER2+/Low IBC
  NCT05795101 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 3 locations
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
  NCT03606967 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations

Common questions

How many trials study Durvalumab for Breast cancer?

9 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.